IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis - Episode 14

Lebrikizumab in Patients With Skin of Color (ADmirable)

Published on: February 25, 2025

Linda Stein Gold, MD, Alexandra K. Golant, MD, Peter Lio, MD , Jennifer Soung, MD

Panelists discuss the limited data on atopic dermatitis (AD) treatments in patients with skin of color, highlighting findings from other studies and real-world data to better understand treatment efficacy and safety in this diverse patient population.

EP. 1: Heterogenous Presentation Of Atopic Dermatitis

EP. 2: Use of Biopsy and Diagnosing New-Onset AD

EP. 3: Treatment Options in Atopic Dermatitis

EP. 4: Improvement in Standard of Care in Atopic Dermatitis

EP. 5: Improvement in Patients’ Qualify of Life with Atopic Dermatitis Treatments

EP. 6: Guidance for Moving to Advanced Systemic Therapy and Biologic Agents

EP. 7: IL-13–Targeting Agents in Atopic dermatitis

EP. 8: Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

EP. 9: Less Frequent Administration of Lebrikizumab for Atopic Dermatitis

EP. 10: Switching or Staying Within the Treatment Class

EP. 11: Use of Combination Therapy in Atopic Dermatitis

EP. 12: Safety Data With Biologics in Atopic Dermatitis

EP. 13: Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice

Now Viewing

EP. 14: Lebrikizumab in Patients With Skin of Color (ADmirable)

EP. 15: Treatment Nonresponders in Atopic Dermatitis

EP. 16: Considerations for Switching Treatment

EP. 17: Emerging Treatment Options in Atopic Dermatitis

Video content above is prompted by the following:

AD is fairly common in patients with skin of color, but we have limited data with AD drugs in these patients.
Please discuss data from other studies, including any real-world data.